Published June 4, 2019
| Version v1
Patent
Open
IL13Ra2 binding agents and use thereof in cancer treatment
Contributors
Patent applicant:
Description
Provided are specific binding molecules, or fragments thereof, that bind to an epitope of IL13Rα2, a receptor polypeptide preferentially found on the surface of cancer cells rather than healthy cells. Exemplary specific binding molecules are bispecific binding molecules that comprise a fragment of an IL13Rα2 binding molecule and a peptide providing a second function providing a signaling function of the signaling domain of a T cell signaling protein, a peptide modulator of T cell activation, or an enzymatic component of a labeling system. Also provided are polynucleotides encoding such a specific binding molecule (e.g., bispecific binding molecule), vectors, host cells, pharmaceutical compositions and methods of preventing, treating or ameliorating a symptom associated with a cancer disease such as a solid tumor disease (e.g., glioblastoma multiforme).
Files
US10308719.pdf
Files
(5.9 MB)
| Name | Size | Download all |
|---|---|---|
|
md5:f12ca92b31e3623fe8dd7324d561193d
|
5.9 MB | Preview Download |
Additional details
Identifiers
- Patent number
- US 10308719 B2
- Patent application number
- US 201615545945 A
- Other
- oai:uchicago.tind.io:6958
Dates
- Patent filed
-
2016-01-26